JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Near Add Your Location
Sorting 15 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
- Accepting patients
- Show Principal Investigator
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Accepting patients
Memorial Sloan Kettering Westchester
West Harrison, NY
- Accepting patients
- Show Principal Investigator
Memorial Sloan Kettering Commack
Commack, NY
- Accepting patients
- Show Principal Investigator
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Accepting patients
Memorial Sloan Kettering Bergen
Montvale, NJ
- Accepting patients
- Show Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown, NJ
- Accepting patients
- Show Principal Investigator
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.